Buprenorphine in Pregnancy Safe for Long-Term Child Development, Study Finds

Medication-assisted treatment with buprenorphine during pregnancy does not increase the risk of long-term neurodevelopmental problems in children, according to a major new study, welcome news for pregnant women managing opioid use disorder who need safe, evidence-based care.

The findings, published April 17, 2026 in The BMJ, draw on US Medicaid data covering more than 2.5 million live births and offer the most robust long-term evidence to date on the safety of buprenorphine for both mother and child.

Why Medication-Assisted Treatment Matters in Pregnancy

Opioid use disorder (OUD) during pregnancy is a serious medical condition that requires careful management. Abrupt withdrawal from opioids without medical supervision can be dangerous for both the pregnant person and the developing fetus, which is why clinical guidelines recommend against unsupervised opioid detox during pregnancy.

Instead, medication-assisted treatment, the use of FDA-approved medications like buprenorphine or methadone alongside counseling and support, is the standard of care.

MAT stabilizes the patient, reduces withdrawal symptoms, and lowers the risk of relapse and overdose. For pregnant women, it also protects fetal health by preventing repeated cycles of intoxication and withdrawal.

Until now, however, long-term data on how prenatal buprenorphine exposure affects child development was limited. This new study closes a critical gap.

What the BMJ Study Found

Researchers used Medicaid data for over 2.5 million live births from 2000 to 2018 to compare neurodevelopmental outcomes in more than 12,000 children exposed to buprenorphine before birth against roughly 5,400 children exposed to methadone.

Children were tracked up to age 8 for conditions including autism, ADHD, speech or language disorder, behavioral disorder and intellectual disability.

The results were reassuring. After adjusting for a range of factors, including maternal age, ethnicity, tobacco and alcohol use, mental health conditions and use of other medications, children prenatally exposed to buprenorphine had a 19% lower risk of any neurodevelopmental disorder by age 8 compared with those exposed to methadone.

Specific condition-by-condition comparisons also favored treatment with buprenorphine. Prenatal buprenorphine exposure was associated with an 11% lower risk of ADHD, a 16% lower risk of speech or language disorder, and a 26% lower risk of autism compared with methadone exposure.

Understanding Buprenorphine as an Opioid Detox Medication

Buprenorphine (sold under brand names including Suboxone and Subutex) is a partial opioid agonist, meaning it activates opioid receptors in the brain enough to prevent withdrawal symptoms and cravings, but with a ceiling effect that limits the risk of misuse and overdose.

When used as part of a supervised medical detox or long-term MAT program, it is highly effective for opioid use disorder.

For pregnant patients, buprenorphine is typically preferred over methadone because earlier research already showed it was associated with fewer short-term complications for newborns. This new BMJ study now extends that evidence to long-term neurodevelopmental safety.

Methadone Remains an Important Option

While buprenorphine showed an advantage in this study, Australian researchers writing a linked editorial in The BMJ emphasized methadone’s continued importance for patients with higher opioid tolerance or more complex clinical needs.

The choice between treating with methadone or buprenorphine should always be made in consultation with a medical provider who can evaluate individual circumstances.

Both medications require medical supervision. Attempting opioid detox during pregnancy without physician oversight, or substituting unproven “natural detox” methods, puts both the pregnant person and the fetus at serious risk and is not supported by evidence.

What This Means for Opioid Detox Programs

The study’s authors concluded that findings support buprenorphine as a safe treatment option for opioid use disorder during pregnancy, adding that further research is needed on newer formulations such as long-acting injectable buprenorphine, which has not yet been studied in pregnancy.

For anyone seeking opioid detox, pregnant or not, the takeaway is that medication-assisted treatment with buprenorphine is evidence-based, clinically proven and now supported by some of the strongest long-term safety data available.

Finding Medical Detox and MAT Programs

If you or someone you love is managing opioid dependence and looking for medical detox programs or medication-assisted treatment, professional guidance is essential.

Medical detox centers provide the supervision needed to safely begin treatment with buprenorphine or methadone, manage withdrawal symptoms, and transition into a longer-term recovery plan.

Call 800-996-6135(Sponsored) to speak with a specialist about medically supervised detox programs near you or search Detox.com’s directory of certified detox centers.